Director, HTA, Value & Evidence (HV&E), I&I / Brepocitinib (Med Rheum)

The Director, Value & Evidence – Brepocitinib will support the strategic goals of the Inflammation & Immunology Business Unit by driving optimal launch and patient access for Brepocitinib through the generation, integration, and translation of robust value and evidence.

This role directly impacts Pfizer’s ability to achieve global access and reimbursement objectives by providing strategic leadership and execution of Health Technology Assessment, Value & Evidence (HV&E) activities that demonstrate the value of Brepocitinib across its lifecycle, including launch and post-launch phases.

This role is part of a collaborative Brepocitinib HV&E team structure, working alongside existing team members to jointly deliver launch and lifecycle evidence. The Director will partner with the Brepocitinib HV&E team to develop and execute the global value and evidence generation strategy for Brepocitinib, including supporting oversight of evidence generation activities and dissemination of technical deliverables in close partnership with GASP, cross-functional and alliance teams.

This position will function with a one "Global Value & Access” mindset and work in a closely aligned manner with GASP, Medical, Clinical, Value & Access, Commercial, and alliance partners to ensure a single, coordinated view on evidence strategy and delivery for Brepocitinib globally. 

ROLE RESPONSIBILITIES

• Drive, together with the Brepocitinib HV&E team, the development and execution of the global value and evidence generation strategy to support the value of Brepocitinib in close partnership with the cross-functional matrix team.
• Support and coordinate, together with the Brepocitinib HV&E colleagues, input from global and country teams on evidence needs and ensure alignment and integration into a coherent global evidence strategy across launch and lifecycle.
• Lead the review, interpretation, and translation of clinical trial outputs, including Clinical Study Reports (CSRs), to identify HEOR-relevant insights, evidence gaps, and post-hoc analytical needs.
• Working as part of the Brepocitinib HV&E team, contribute to the design, execution, and oversight of HV&E studies, including:
• Cost-effectiveness and budget impact models
• Indirect treatment comparisons / network meta-analyses
• Systematic literature reviews (clinical, economic, humanistic, epidemiology)
• Patient-reported outcome and quality-of-life evidence generation
• Real-world evidence studies (e.g., treatment patterns, burden of disease, epidemiology, real-world effectiveness)
• Develop and maintain global value narratives and evidence deliverables (e.g., Global Value Dossiers .. etc) to support HTA submissions and payer decision-making.
• Engage with cross-functional clinical development teams to ensure the evidence strategy is optimally positioned to support rapid and broad access upon launch.
• Collaborate closely with alliance partners, jointly representing the Brepocitinib HV&E team, to align on evidence strategy, roles, and execution responsibilities.
• Develop strategic external partnerships and research collaborations with key experts, HTA stakeholders, and academic institutions as appropriate.
• Manage HV&E budgets and vendor relationships effectively.
• Ensure all activities are conducted in compliance with Pfizer SOPs, governance, and regulatory requirements.

BASIC QUALIFICATIONS

Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.

• Graduate degree required (e.g. MSc, MPH, PhD)
• 7+ years of experience with MSc/MPH/MBA degree; 5+ years with PharmD/PhD in HEOR or relevant related fields (health economics, epidemiology, health services research, or other research-focused public health field)
• Demonstrated depth of understanding of fundamental health services research methods and tools, including:
• Health economic modeling
• Cost-effectiveness and budget impact analyses
• Indirect treatment comparisons
• Patient-reported outcomes and quality-of-life measures
• Real-world evidence study